Sutro Biopharma Net Income
| STRO Stock | USD 17.43 0.79 4.75% |
As of the 19th of February, Sutro Biopharma has the Semi Deviation of 4.75, risk adjusted performance of 0.1786, and Coefficient Of Variation of 466.11. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Sutro Biopharma, as well as the relationship between them.
Sutro Biopharma Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 1.0612 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -204.7 M | -194.5 M | |
| Net Loss | -107.3 M | -101.9 M | |
| Net Loss | -204.7 M | -194.5 M | |
| Net Loss | (34.05) | (32.34) | |
| Net Income Per E B T | 1.16 | 1.19 |
Sutro | Net Income | Build AI portfolio with Sutro Stock |
Evaluating Sutro Biopharma's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Sutro Biopharma's fundamental strength.
Latest Sutro Biopharma's Net Income Growth Pattern
Below is the plot of the Net Income of Sutro Biopharma over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Sutro Biopharma financial statement analysis. It represents the amount of money remaining after all of Sutro Biopharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Sutro Biopharma's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sutro Biopharma's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (227.46 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Sutro Net Income Regression Statistics
| Arithmetic Mean | (64,067,827) | |
| Geometric Mean | 16,724,846 | |
| Coefficient Of Variation | (125.98) | |
| Mean Deviation | 67,503,893 | |
| Median | (32,128,000) | |
| Standard Deviation | 80,714,220 | |
| Sample Variance | 6514.8T | |
| Range | 229.2M | |
| R-Value | (0.90) | |
| Mean Square Error | 1374.6T | |
| R-Squared | 0.80 | |
| Slope | (14,315,884) | |
| Total Sum of Squares | 104236.6T |
Sutro Net Income History
Other Fundumenentals of Sutro Biopharma
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Sutro Biopharma Net Income component correlations
Sutro Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Sutro Biopharma is extremely important. It helps to project a fair market value of Sutro Stock properly, considering its historical fundamentals such as Net Income. Since Sutro Biopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Sutro Biopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Sutro Biopharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Sutro diversify its offerings? Factors like these will boost the valuation of Sutro Biopharma. If investors know Sutro will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Sutro Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (2.60) | Revenue Per Share | Quarterly Revenue Growth 0.138 | Return On Assets | Return On Equity |
Understanding Sutro Biopharma requires distinguishing between market price and book value, where the latter reflects Sutro's accounting equity. The concept of intrinsic value - what Sutro Biopharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Sutro Biopharma's price substantially above or below its fundamental value.
Please note, there is a significant difference between Sutro Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sutro Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Sutro Biopharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Sutro Biopharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Sutro Biopharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Sutro Biopharma.
| 11/21/2025 |
| 02/19/2026 |
If you would invest 0.00 in Sutro Biopharma on November 21, 2025 and sell it all today you would earn a total of 0.00 from holding Sutro Biopharma or generate 0.0% return on investment in Sutro Biopharma over 90 days. Sutro Biopharma is related to or competes with Artiva Biotherapeutics, Precision BioSciences, Pliant Therapeutics, Fractyl Health, InflaRx NV, Metagenomi Common, and Connect Biopharma. Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company More
Sutro Biopharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Sutro Biopharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Sutro Biopharma upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 5.81 | |||
| Information Ratio | 0.2072 | |||
| Maximum Drawdown | 29.1 | |||
| Value At Risk | (7.78) | |||
| Potential Upside | 11.87 |
Sutro Biopharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sutro Biopharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Sutro Biopharma's standard deviation. In reality, there are many statistical measures that can use Sutro Biopharma historical prices to predict the future Sutro Biopharma's volatility.| Risk Adjusted Performance | 0.1786 | |||
| Jensen Alpha | 1.29 | |||
| Total Risk Alpha | 1.06 | |||
| Sortino Ratio | 0.2257 | |||
| Treynor Ratio | 0.8702 |
Sutro Biopharma February 19, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1786 | |||
| Market Risk Adjusted Performance | 0.8802 | |||
| Mean Deviation | 4.85 | |||
| Semi Deviation | 4.75 | |||
| Downside Deviation | 5.81 | |||
| Coefficient Of Variation | 466.11 | |||
| Standard Deviation | 6.33 | |||
| Variance | 40.09 | |||
| Information Ratio | 0.2072 | |||
| Jensen Alpha | 1.29 | |||
| Total Risk Alpha | 1.06 | |||
| Sortino Ratio | 0.2257 | |||
| Treynor Ratio | 0.8702 | |||
| Maximum Drawdown | 29.1 | |||
| Value At Risk | (7.78) | |||
| Potential Upside | 11.87 | |||
| Downside Variance | 33.77 | |||
| Semi Variance | 22.52 | |||
| Expected Short fall | (5.41) | |||
| Skewness | 0.4425 | |||
| Kurtosis | 0.7976 |
Sutro Biopharma Backtested Returns
Sutro Biopharma is slightly risky given 3 months investment horizon. Sutro Biopharma owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.23, which indicates the firm had a 0.23 % return per unit of risk over the last 3 months. We were able to interpolate data for twenty-nine different technical indicators, which can help you to evaluate if expected returns of 1.43% are justified by taking the suggested risk. Use Sutro Biopharma Coefficient Of Variation of 466.11, semi deviation of 4.75, and Risk Adjusted Performance of 0.1786 to evaluate company specific risk that cannot be diversified away. Sutro Biopharma holds a performance score of 18 on a scale of zero to a hundred. The entity has a beta of 1.55, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Sutro Biopharma will likely underperform. Use Sutro Biopharma sortino ratio, semi variance, as well as the relationship between the Semi Variance and rate of daily change , to analyze future returns on Sutro Biopharma.
Auto-correlation | 0.64 |
Good predictability
Sutro Biopharma has good predictability. Overlapping area represents the amount of predictability between Sutro Biopharma time series from 21st of November 2025 to 5th of January 2026 and 5th of January 2026 to 19th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Sutro Biopharma price movement. The serial correlation of 0.64 indicates that roughly 64.0% of current Sutro Biopharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.64 | |
| Spearman Rank Test | 0.65 | |
| Residual Average | 0.0 | |
| Price Variance | 3.18 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Sutro Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Sutro Biopharma reported net income of (227.46 Million). This is 166.65% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 139.84% higher than that of the company.
Sutro Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sutro Biopharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sutro Biopharma could also be used in its relative valuation, which is a method of valuing Sutro Biopharma by comparing valuation metrics of similar companies.Sutro Biopharma is currently under evaluation in net income category among its peers.
Sutro Biopharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Sutro Biopharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Sutro Biopharma's managers, analysts, and investors.Environmental | Governance | Social |
Sutro Biopharma Institutional Holders
Institutional Holdings refers to the ownership stake in Sutro Biopharma that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Sutro Biopharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Sutro Biopharma's value.| Shares | Adage Capital Partners Gp Llc | 2025-06-30 | 2 M | Ubs Group Ag | 2025-06-30 | 1.6 M | Aqr Capital Management Llc | 2025-06-30 | 1 M | Renaissance Technologies Corp | 2025-06-30 | 913.2 K | Geode Capital Management, Llc | 2025-06-30 | 816.9 K | Affinity Asset Advisors, Llc | 2025-06-30 | 752.7 K | Jane Street Group Llc | 2025-06-30 | 688.9 K | Dimensional Fund Advisors, Inc. | 2025-06-30 | 628.5 K | Dafna Capital Management Llc | 2025-06-30 | 437.1 K | Suvretta Capital Management, Llc | 2025-06-30 | 6.5 M | Kynam Capital Management, Lp | 2025-06-30 | 5.1 M |
Sutro Fundamentals
| Return On Equity | -18.1 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (2.05) % | ||||
| Operating Margin | (4.01) % | ||||
| Current Valuation | 114.89 M | ||||
| Shares Outstanding | 85.14 M | ||||
| Shares Owned By Insiders | 4.68 % | ||||
| Shares Owned By Institutions | 67.55 % | ||||
| Number Of Shares Shorted | 591.3 K | ||||
| Price To Earning | 53.08 X | ||||
| Price To Book | 2.11 X | ||||
| Price To Sales | 2.58 X | ||||
| Revenue | 62.04 M | ||||
| Gross Profit | 274.15 M | ||||
| EBITDA | (180.45 M) | ||||
| Net Income | (227.46 M) | ||||
| Cash And Equivalents | 225.64 M | ||||
| Cash Per Share | 4.33 X | ||||
| Total Debt | 23.15 M | ||||
| Debt To Equity | 0.27 % | ||||
| Current Ratio | 7.44 X | ||||
| Book Value Per Share | (1.02) X | ||||
| Cash Flow From Operations | (191.54 M) | ||||
| Short Ratio | 2.37 X | ||||
| Earnings Per Share | (2.60) X | ||||
| Price To Earnings To Growth | 0.12 X | ||||
| Target Price | 2.69 | ||||
| Number Of Employees | 178 | ||||
| Beta | 1.61 | ||||
| Market Capitalization | 79.09 M | ||||
| Total Asset | 387.21 M | ||||
| Retained Earnings | (786.87 M) | ||||
| Working Capital | 211.42 M | ||||
| Net Asset | 387.21 M |
About Sutro Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sutro Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sutro Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sutro Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Sutro Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sutro Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sutro Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Sutro Stock
| 0.79 | GXEA | Galapagos NV Earnings Call This Week | PairCorr |
| 0.77 | 8VP1 | AVRICORE HEALTH INC | PairCorr |
| 0.69 | EQ | Equillium | PairCorr |
Moving against Sutro Stock
| 0.73 | OSE | OSE Pharma SA | PairCorr |
| 0.69 | RAC | Race Oncology Earnings Call This Week | PairCorr |
| 0.67 | VCYT | Veracyte Earnings Call This Week | PairCorr |
| 0.67 | DRMA | Dermata Therapeutics | PairCorr |
| 0.44 | VCEL | Vericel Corp Ord Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Sutro Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sutro Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sutro Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sutro Biopharma to buy it.
The correlation of Sutro Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sutro Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sutro Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sutro Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Will Biotechnology sector continue expanding? Could Sutro diversify its offerings? Factors like these will boost the valuation of Sutro Biopharma. If investors know Sutro will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Sutro Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (2.60) | Revenue Per Share | Quarterly Revenue Growth 0.138 | Return On Assets | Return On Equity |
Understanding Sutro Biopharma requires distinguishing between market price and book value, where the latter reflects Sutro's accounting equity. The concept of intrinsic value - what Sutro Biopharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Sutro Biopharma's price substantially above or below its fundamental value.
Please note, there is a significant difference between Sutro Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sutro Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Sutro Biopharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.